Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection

NCT06250634 | Completed

• 1 other identifier: Fast 21292, Fast 23359
• Study Type: interventional
• Target: 806
• Locations: 1 country
• Sites: 1

Brief Summary

This study intends to collect the clinical data of patients with Helicobacter pylori infection, and to observe and count the high-dose double therapy and the traditional quadruple / triple therapy ( i.e., esomeprazole + amoxicillin double high-dose double therapy and esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate traditional quadruple therapy or Vonoprazan + amoxicillin double high-dose double therapy and Vonoprazan + amoxicillin + clarithromycin triple therapy ). The eradication rate of Helicobacter pylori was compared between the two different regimens respectively, and the efficacy, safety and compliance of different regimens were compared. It provides a new reference for clinical treatment of Helicobacter pylori, and has great clinical value and significance for simplifying the anti-Helicobacter-pylori treatment plan, increasing patient compliance, and exploring efficient anti-Helicobacter-pylori therapy suitable for the Chinese population.

Conditions

Helicobacter Pylori Infection

Outcome Measures

Primary Outcomes (1)

• Helicobacter pylori eradication rate

  carbon-13/14 urea breath test

  pre-intervention and at least 30 days post-intervention

Secondary Outcomes (2)

• Adverse events

  the 3rd, 7th, and 14th day during the intervention

• Compliance

  the 14th day during the intervention

Study Arms (4)

Double group ( Esomeprazole )

EXPERIMENTAL

Drug: esomeprazole + amoxicillin

Quadruple group ( Esomeprazole )

ACTIVE COMPARATOR

Drug: esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent

Double group ( Vonoprazan )

EXPERIMENTAL

Drug: Vonoprazan + amoxicillin

Triple group (Vonoprazan )

ACTIVE COMPARATOR

Drug: Vonoprazan + amoxicillin + clarithromycin

Interventions

esomeprazole + amoxicillin DRUG

esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily

Double group ( Esomeprazole )

esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent DRUG

20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)

Quadruple group ( Esomeprazole )

Vonoprazan + amoxicillin DRUG

20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)

Double group ( Vonoprazan )

Vonoprazan + amoxicillin + clarithromycin DRUG

20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)

Triple group (Vonoprazan )

Eligibility Criteria

• Age: 14 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• patients aged 14-90 years, no requirement for gender;
• patients diagnosed as H. pylori infection by at least one of the following tests: carbon-13/14 urea breath test (13C/14C-UBT) or immuno-histochemical staining of biopsy specimens;
• patients with no use of antibiotics, bismuth or Chinese traditional medicines with antibacterial effects in the previous 4 weeks of 13C/14C-UBT, and no H2 receptor antagonists, PPIs, P-CAB or other drugs affecting H .pylori activity within the previous 2 weeks of 13C/14C-UBT;
• patients without history of receiving H. pylori eradication therapy.

You may not qualify if:

• patients with serious diseases or clinical conditions that may interfere with the evaluation of the results of the study, such as severe heart, liver, lung, and renal insufficiency, low immunity, and so on;
• patients with allergy to penicillin or any research-program-related drugs;
• patients with mental illness and communication disorders;
• patients in pregnancy or lactation;
• patients with severe gastrointestinal diseases, such as gastrointestinal tumors, gastrointestinal bleeding, other organic diseases, etc.;
• patients who were participating in other clinical trials;
• patients who were considered inappropriate for enrollment after evaluation by the researchers.

Sponsors & Collaborators

• The Third Xiangya Hospital of Central South University: lead
• The Second People's Hospital of Huaihua: collaborator
• Yueyang Hospital of Traditional Chinese Medicine: collaborator

Study Sites (1)

outpatient department of gastroenterology of the Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China

Location

MeSH Terms

Interventions

Esomeprazole; Amoxicillin; Clarithromycin; 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

Intervention Hierarchy (Ancestors)

Omeprazole; 2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Ampicillin; Penicillin G; Penicillins; beta-Lactams; Lactams; Amides; Erythromycin; Macrolides; Polyketides; Lactones

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 18, 2024
• First Posted: February 9, 2024
• Study Start: February 10, 2024
• Primary Completion: May 10, 2024
• Study Completion: May 10, 2024
• Last Updated: May 29, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)